Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: Results from the German RABBIT cohort

Annals of the Rheumatic Diseases

Volumn 76, Issue 9, 2017, Pages 1583-1590

  Meissner, Y ^a   Richter, A ^a   Manger, B ^b   Tony, Hp ^c   Wilden, E ^d   Listing, J ^a   Zink, A ^a   Strangfeld, A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d Rheumatologist   (Germany)

Author keywords

rheumatoid arthritis stroke cerebrovascular events serious adverse events multi state models

Indexed keywords

ABATACEPT; ADALIMUMAB; ANAKINRA; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CYCLOHEXANONE DERIVATIVE; PHENOL DERIVATIVE; XOCHITLOLDIONE;

ADULT; ADVERSE EVENT; AGE; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DIABETES MELLITUS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GENDER; HEART FAILURE; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; INCIDENCE; INFECTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OSTEOPOROSIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; RISK FACTOR; SERIOUS ADVERSE EVENT; SMOKING; SUBARACHNOID HEMORRHAGE; TRANSIENT ISCHEMIC ATTACK; AGED; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; GERMANY; HYPOLIPOPROTEINEMIAS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; ISCHEMIC ATTACK, TRANSIENT; PROPORTIONAL HAZARDS MODEL; REGISTER; STROKE;

ADULT; AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CYCLOHEXANONES; FEMALE; GERMANY; HUMANS; HYPOLIPOPROTEINEMIAS; IMMUNOCOMPROMISED HOST; INCIDENCE; INFECTION; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PHENOLS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; SMOKING; STROKE;

EID: 85028005532     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211209     Document Type: Article

References (37)

1. Truelsen T, Begg S, Mathers C. The global burden of cerebrovascular disease. http://wwwwhoint/healthinfo/statistics/bod-cerebrovasculardiseasestrokepdf (accessed 18 October 2016).
2. O'Donnell MJ, Xavier D, Liu L, et al. INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010;376:112-23.
3. Ovbiagele B, Nguyen-Huynh MN. Stroke epidemiology: Advancing our understanding of disease mechanism and therapy. Neurotherapeutics 2011;8:319-29.
4. Wiseman SJ, Ralston SH, Wardlaw JM. Cerebrovascular disease in rheumatic diseases: A systematic review and Meta-Analysis. Stroke 2016;47:943-50.
5. Nadareishvili Z, Michaud K, Hallenbeck JM, et al. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: A nested, case-control study. Arthritis Rheum 2008;59:1090-6.
6. Zhang J, Chen L, Delzell E, et al. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2014;73:1301-8.
7. Navarro-Millán I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: Data from the National Veterans Health Administration. Ann Rheum Dis 2016;75:341-7.
8. Palm F, Urbanek C, Grau A. Infection, its treatment and the risk for stroke. Curr Vasc Pharmacol 2009;7:146-52.
9. Emsley HC, Hopkins SJ. Acute ischaemic stroke and infection: Recent and emerging concepts. Lancet Neurol 2008;7:341-53.
10. Nadav L, Gur AY, Korczyn AD, et al. Stroke in hospitalized patients: Are there special risk factors? Cerebrovasc Dis 2002;13:127-31.
11. Navi BB, Reiner AS, Kamel H, et al. Association between incident cancer and subsequent stroke. Ann Neurol 2015;77:291-300.
12. Calabrese LH, Xie F, Yun H, et al. Herpes Zoster and the risk of Stroke in Patients with autoimmune diseases. Arthritis Rheumatol 2017;69:439-46.
13. Lautenschläger J, Mau W, Kohlmann T, et al. [Comparative evaluation of a german version of the Health Assessment Questionnaire and the Hannover functional capacity questionnaire]. Z Rheumatol 1997;56:144-55.
14. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44.
15. Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: The impact of disease activity, treatment with glucocorticoids, tnfinhibitors and rituximab. Ann Rheum Dis 2015;74:415-21.
16. Richter A, Meissner Y, Strangfeld A, et al. Primary and secondary patient data in contrast: The use of observational studies like RABBIT. Clin Exp Rheumatol 2016;101:79-86.
17. Brown E. Medical Dictionary for Regulatory activities (MedDRA® ). Pharmacovigilance: John Wiley & Sons, Ltd 2007:168-83.
18. Therneau T, Grambsch P. Modeling Survival Data: Extending the cox model: Springer-Verlag, 2000.
19. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: Competing risks and multistate models. Stat Med 2007;26:2389-430.
20. Beyersmann J, Allignol A, Schumacher M. Competing risks and multistate models with R: Springer, 2011.
21. Hansen BB, Klopfer SO, Klopfer Olsen S. Optimal full matching and related designs via network flows. J Comp Graph Stat 2006;15:609-27.
22. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611-8.
23. Kimura K, Minematsu K, Yamaguchi T. Characteristics of in-hospital onset ischemic stroke. Eur Neurol 2006;55:155-9.
24. Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:842-5.
25. van Breukelen-van der Stoep DF, van Zeben D, Klop B, et al. Marked underdiagnosis and undertreatment of hypertension and hypercholesterolaemia in rheumatoid arthritis. Rheumatology 2016;55:1210-6.
26. Desai SS, Myles JD, Kaplan MJ. Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: A cohort analysis. Arthritis Res Ther 2012;14:R270.
27. Zamora-Legoff JA, Myasoedova E, Matteson EL, et al. Drug prescribing trends in adults with rheumatoid arthritis: A population-based comparative study from 2005 to 2014. Clin Rheumatol 2016;35:2427-36.
28. Meissner Y, Zink A, Kekow J, et al. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther 2016;18:183.
29. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17-28.
30. Low AS, Lunt M, Mercer LK, et al. Association between ischemic stroke and tumor necrosis factor inhibitor therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2016;68:1337-45.
31. Solomon DH, Curtis JR, Saag KG, et al. Cardiovascular risk in rheumatoid arthritis: Comparing TNF-blockade with nonbiologic DMARDs. Am J Med 2013;126:730. e9-730.e17.
32. Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790-8.
33. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82.
34. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004;90:859-65.
35. Avinã-Zubieta JA, Abrahamowicz M, Choi HK, et al. Risk of cerebrovascular disease associated with the use of glucocorticoids in patients with incident rheumatoid arthritis: A population-based study. Ann Rheum Dis 2011;70:990-5.
36. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:3754-832.
37. Holmqvist M, Gränsmark E, Mantel A, et al. Occurrence and relative risk of stroke in incident and prevalent contemporary rheumatoid arthritis. Ann Rheum Dis 2013;72:541-6.